Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 869

1.

Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.

Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A.

Cancer Res. 2002 Dec 1;62(23):6884-90.

2.

Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor.

Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Laïn G, Gionnet K, Goncalvès M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A.

J Biol Chem. 2003 Sep 12;278(37):35564-73. Epub 2003 Jul 1.

3.

Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.

Jia H, Jezequel S, Löhr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I.

Biochem Biophys Res Commun. 2001 Apr 27;283(1):164-73.

PMID:
11322784
4.

A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.

Hagedorn M, Zilberberg L, Lozano RM, Cuevas P, Canron X, Redondo-Horcajo M, Gimenez-Gallego G, Bikfalvi A.

FASEB J. 2001 Mar;15(3):550-2. Epub 2001 Jan 5.

PMID:
11259363
5.

The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.

6.

Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.

Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD.

Circulation. 1999 Sep 28;100(13):1423-31.

PMID:
10500044
7.

Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a).

Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, Jung KH, Park DH, Yoon Y, Byun SM, Chung SI.

J Biol Chem. 2003 Aug 1;278(31):29000-8. Epub 2003 May 13.

8.

Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.

Chillemi F, Francescato P, Ragg E, Cattaneo MG, Pola S, Vicentini L.

J Med Chem. 2003 Sep 11;46(19):4165-72.

PMID:
12954068
9.
10.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

11.

Kallistatin is a new inhibitor of angiogenesis and tumor growth.

Miao RQ, Agata J, Chao L, Chao J.

Blood. 2002 Nov 1;100(9):3245-52.

12.

The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.

Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L.

Cancer Res. 2004 Dec 15;64(24):9012-7.

13.
14.

Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action.

Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A.

Blood. 1999 Aug 1;94(3):984-93.

15.

Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.

Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.

Nat Med. 2003 Aug;9(8):1026-32. Epub 2003 Jul 20.

PMID:
12872165
16.

Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.

Abe M, Inoue D, Matsunaga K, Ohizumi Y, Ueda H, Asano T, Murakami M, Sato Y.

J Cell Physiol. 2002 Jan;190(1):109-16.

PMID:
11807817
17.

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.

Mol Cancer Res. 2002 Nov;1(1):2-11.

18.

A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor.

Tan DC, Kini RM, Jois SD, Lim DK, Xin L, Ge R.

FEBS Lett. 2001 Apr 13;494(3):150-6.

19.

Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.

Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.

Cancer Lett. 2010 Feb 28;288(2):251-60. doi: 10.1016/j.canlet.2009.07.008. Epub 2009 Aug 6.

PMID:
19664879

Supplemental Content

Support Center